Mild adverse events were reported including intraocular inflammation as well as anterior chamber inflammation.107,108 Following this trial, two phase III clinical studies, RESCUE and REVERSE, evaluated the efficacy and safety of unilateral intravitreal injection of rAAV2-ND4 into ND4-LHON patients who had vision loss <6 months (NCT02652767, RESCUE) or between 6 and 12 months (NCT02652780, REVERSE). This evidence concerns the gene MT-ND4 and Leber hereditary optic neuropathy.